According to a statement from KT&G, due to its 15-year long-term supply agreement with Phillip Morris International (PMI) for Next Generation Products (NGP), the overseas business is stabilizing and there is a sharp increase in demand for the highly profitable HNBpod sales. Consequently, KT&G has decided to ensure overseas production capacity and plans to establish its first HNBpod production factory overseas.
Additionally, in order to capture the Eastern Europe and Central Asia markets, HNBpod's production factories will be located in countries within Eastern Europe and Kazakhstan.
KT&G believes that Eastern Europe is a strategic location to capture the global market for cigarette-type electronic cigarettes and establish a strong presence in Europe. Kazakhstan is being targeted for its potential growth in the Central Asian markets of Uzbekistan and Kyrgyzstan. Although the size of investment has not yet been determined, KT&G has mapped out a blueprint with its mid-to-long-term growth strategy.
During a discussion with Boston Consulting Group, KT&G revealed its plan to invest 1.2 trillion Korean won ($957 million) in the NGP (Next Generation Product) field over the next five years, with a majority of the funds going towards establishing overseas factories.
KT&G previously established cigarette (CC) factories in Russia, Indonesia, and Turkey but encountered difficulties in quickly establishing a distribution network. In contrast, the cigarette-shaped electronic cigarette quickly grew after signing a contract with PMI, which has a global distribution channel. From the export of three countries including Japan in 2020, the number of export countries increased to 31 as of early this year. Currently, "Icos" related products are sold to 70 countries. PMI aims to expand to 100 countries by 2025, and KT&G's NGP export countries are expected to increase to this level.
According to major securities firms both domestic and international, it is predicted that KT&G's sales revenue will increase by 7-8 times in 15 years. Recently, JP Morgan and Hana Investment & Securities respectively released forecast reports for the end of the PMI and electronic cigarette long-term contracts (in 2037), stating that NGP sales revenue will be 58 trillion Korean Won (4.62 billion USD) and 66 trillion Korean Won (5.25 billion USD).
KT&G has predicted through these reports that annual sales of NGP will increase by 20.6%, while revenue will grow by 24.0%. Last year, KT&G's NGP sales amounted to approximately 870 billion Korean won ($690 million) both domestically and internationally.
According to a previous confidential agreement with PMI, KT&G's overseas e-cigarette sales will now be disclosed each quarter going forward. Activist funds and other small shareholders have been demanding transparency on KT&G's future growth potential in the NGP field, including overseas sales figures, citing negative effects on the company's stock price. A representative from KT&G stated, "Starting with the February earnings report that includes Q4 performance, we will be disclosing last year's and the previous year's NGP overseas sales figures for the first time. Subsequently, this information will be reflected in our quarterly reports, allowing investors to more thoroughly assess KT&G's growth.
Photo source: Money Today - KT&G President Baek Bok-in and PMI CEO Jacek Olczak shake hands after signing a contract.
Reference:
[Exclusive] KT&G to establish its first overseas e-cigarette factory...in two locations in Eastern Europe and Kazakhstan.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
